Intermountain Healthcare Inks Taiwanese Distribution Deal for NGS Cancer Test | GenomeWeb

NEW YORK (GenomeWeb) – US provider Intermountain Healthcare has signed a distribution deal allowing Taiwan's Prisma Biotech to sell the ICG100 tumor sequencing test in that country.

The next-generation sequencing-based ICG100 test provides analyzes 100 genes for patient-specific mutations that could suggest personalized drug treatments. Intermountain controls the rights to the next-generation sequencing-based test through a contract with Prisma's fully-owned subsidiary, ReadGene.

Financial and other details of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.